European Equities Traded in the US as American Depositary Receipts Rise Slightly Higher in Thursday Trading

MT Newswires Live10-24

European equities traded in the US as American depositary receipts were trending slightly higher late Thursday morning, rising 0.18% to 1,390.31 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by biopharmaceutical company DBV Technologies (DBVT) and 3D printer company Materialise (MTLS), which surged 20% and 15%, respectively. They were followed by medical device maker EDAP TMS (EDAP) and petroleum refiner Equinor (EQNR), which rose 3.4% and 2.8%, respectively.

The decliners from continental Europe were led by semiconductor company Sequans Communications (SQNS), which fell 2.1% and then biopharmaceutical company Grifols (GRFS) retreated 1.2%. They were followed by pharmaceutical company Novo Nordisk (NVO) and telecommunications company VEON (VEON), which were down 1% and 0.6%, respectively.

From the UK and Ireland, the gainers were led by biotech firm Trinity Biotech (TRIB), which added 19%, and then biopharmaceutical firm Akari Therapeutics (AKTX), which gained 11%. Financial services company Barclays (BCS) and Lloyds Banking Group (LYG) increased 5.5% and 1.4%, respectively.

The decliners from the UK and Ireland were led by biopharmaceutical companies TC Biopharm (TCBP) and Adaptimmune Therapeutics (ADAP), which lost 12% and 1.9%, respectively. They were followed by biopharmaceutical company Biodexa Pharmaceuticals (BDRX) and biotech firm Autolus Therapeutics (AUTL), which were down 1.7% and 1.3%, respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment